Ocugen

Ocugen is pleased to announce the appointment of Rita Johnson-Greene, MBA, to Chief Financial Officer! With more than 20 years of healthcare leadership experience—including cell and gene therapy—Mrs. Johnson-Greene joins us at a transformative time for Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this year. We look forward to her leadership while we continue advancing our novel modifier gene therapy platform to address unmet medical needs that still exist for major blindness diseases. “Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Shankar Musunuri, PhD, MBA, Chairman, CEO, and Co-founder.    Read the full press release: https://bit.ly/4r6PIyk #LeadershipAnnouncement #BiotechLeadership

This week is National #PatientRecognitionWeek, a time to honor patients, elevate patient-centered care, and enhance satisfaction across the healthcare industry. Hear from Aiden, an OCU410ST Phase 1 study participant. Aiden was diagnosed with Stargardt disease just as he was entering high school. In a time filled with change and independence, he was now faced with new challenges. After participating in our GARDian OCU410ST Phase 1 study, Aiden is experiencing positive changes in his daily life. Within the last year, it has been easier for him to navigate faces and identify fine details—helping him feel more present, confident, and independent in his everyday activities. By highlighting patient journeys like Aiden’s, we reinforce our commitment to putting patients at the center of everything we do. We are advancing our modifier gene therapies through the clinic with one goal in mind—addressing major blindness diseases to offer hope for patients across the globe. Learn more about our patient's journey: https://bit.ly/3LSHivq #StargardtDisease #ClinicalTrials #GeneTherapy #Ocugen #PatientsFirst

This #BlackHistoryMonth, we honor the origins and purpose of the celebration—recognizing the achievements, resilience, and lasting impact of Black Americans. We also take this time to celebrate Black scientists and innovators who paved the way for progress in science and medicine, shaping a future driven by innovation and representation in healthcare. At Ocugen, we are proud to reflect on this legacy. #BHM #DiversityInSTEM #HealthcareInnovation #Ocugen

CGTLive's latest feature highlights the publication of Phase 1 GARDian1 results for OCU410ST, our novel modifier gene therapy for Stargardt disease. Data shows that OCU410ST was well tolerated with no serious treatment-related adverse events and delivered clinically meaningful visual and structural benefits at 12 months in patients across early to advanced Stargardt disease. Among six BCVA-evaluable patients without confounders, treated eyes gained +6 letters in BCVA (+4.5 letters) compared to a −1.5 letter decline in untreated fellow eyes, reinforcing its potential to address this inherited retinal disease for which no approved therapy exists. The article also shares insights from Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School of Medicine, and Huma Q., MD, MPH, Chief Medical Officer of Ocugen. Read more: https://bit.ly/3LN6S4X   #OCU410ST #GeneTherapy #ClinicalTrials #Biotech  

In our latest OCU410 announcement on positive preliminary 12-month data (~50% of patients evaluated to date) from the Phase 2 ArMaDa clinical trial, we included encouraging 12-month Phase 1 findings where OCU410-treated eyes demonstrated 60% slower loss of the ellipsoid zone (a structural exploratory endpoint) compared to untreated fellow eyes. The 60% reduction in EZ loss rate indicates that OCU410 treatment is substantially slowing the rate of photoreceptor degeneration compared to the natural history observed in the untreated fellow eye of the same patient. Additionally, treated eyes experienced a 20.2% relative reduction in GA lesion growth compared with untreated fellow eyes. Safety has been favorable, with no OCU410-related serious adverse events reported to date. To learn more, review our latest Corporate Presentation: https://bit.ly/4k2YuuK #OCU410 #ClincialTrials #GeographicAtrophy #Biotech 

Nancy was diagnosed with retinitis pigmentosa (RP) 31 years ago. For decades, she watched her vision slowly fade with no real way to change its course. After joining Ocugen’s OCU400 clinical trial, which targets both syndromic and non-syndromic forms of RP with a clinical and/or genetic diagnosis, she began to experience something she had not felt in years: progress. Nancy now has more definition in her left eye, adapts better to light and darkness with her right eye, and no longer needs a magnifier to read. After more than thirty years, Nancy is finally seeing meaningful change and is hopeful for the future. To learn more about Ocugen’s novel modifier gene therapy candidates, with a gene-agnostic approach to treating the entire disease, visit: https://bit.ly/4bjhov5 #OCU400 #RetinitisPigmentosa #ClinicalTrials #GeneTherapy

Patients who pursue treatment with Ocugen’s modifier gene therapies are hoping for a specific outcome—to retain or improve vision. David RP Almeida MD MBA PhD, Vitreoretinal Surgeon and Clinician Scientist, President and CEO of Erie Retina Research, and Founder and President of Case X Global, and a principal investigator, recently sat down to share his experience with Ocugen’s clinical trials and expanded access program (EAP). At Erie Retina Research, 12 subjects have been treated in the OCU400 clinical trial for retinitis pigmentosa, and an additional 20 patients have been treated through our EAP. The OCU400 EAP is available to adult patients with early, intermediate, to advanced retinitis pigmentosa who may benefit from OCU400 prior to FDA approval. Unlike traditional gene therapies or gene editing approaches, our novel modifier gene therapies are designed to address the entire disease with a single, one-time treatment. Contact clinical.request@ocugen.com to learn more about our clinical trials. #RetinitisPigmentosa #ClinicalTrials #Biotech

On this day, we honor a man with a dream, a leader with a purpose, and a force for justice and inclusion. Dr. Martin Luther King Jr.’s vision and commitment towards building a future of equality, compassion, and service continues to inspire us. #MLKDay

What a week for Ocugen at the 44ᵗʰ Annual J.P. Morgan Healthcare Conference! Our Chairman, CEO, and Co-founder, Shankar Musunuri, PhD, MBA, took the stage for the first time to share Ocugen’s story to investors, industry leaders, and potential strategic partners. The presentation highlighted progress of our novel modifier gene therapy pipeline as we work to transform the treatment landscape for major blindness diseases. He also reinforced our regulatory strategy, including plans to submit three Biologics License Applications in three years, beginning this year with OCU400 for retinitis pigmentosa.   Thank you to everyone who connected with us during #JPM26. We look forward to building on this momentum in 2026.   To watch the replay of the presentation, visit https://bit.ly/4qVr4QG. #CouragousInnovation #GeneTherapy #Ophthalmology

Ocugen announced positive preliminary 12-month results from its phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), a novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD): https://ow.ly/bhZO50XY1TJ